The Sapphire has a rechargeable and reloadable fill capacity; it can be activated monthly by inputting a unique, prescription-only authorization code, delivered via a radio-frequency identification card that is mailed to the patient.
The episodic cluster headache trial included a total of 106 patients with an average of 17.5 cluster headache attacks per week at baseline.
Patients with cluster headaches present differently depending on whether they have ever been exposed to tobacco.
The United States Cluster Headache Survey assessed tobacco exposure in individuals with cluster headaches.
Clinicians discuss the clinical implications of headache and comorbid sleep disturbances.
Emerging evidence suggests that sphenopalatine ganglion stimulation may be an effective treatment for refractory cluster headache.
In episodic cluster headaches, acute noninvasive vagus nerve stimulation led to significantly higher rates of participants without pain.
A recently published article exposes a gaping hole in the access to an effective first-line therapy for a portion of patients with cluster headache in the United States.
Cluster headaches are considered the most severe headache type and the most difficult to treat. In 2016, the American Headache Society released new evidence-based guidelines for the treatment of cluster headache.
Tobacco use, alcohol consumption, age at disease onset, and sleep quality are predictors of cluster headache severity.
Results of a recent study found that the current costs of medical grade oxygen for use in the treatment of cluster headache are not "prohibitively expensive" for either healthcare insurance providers or for patients.
Local and painful symptoms and signs and general symptoms occur frequently prior to cluster headache attacks.
gammaCore, a hand-held device for treating episodic cluster headaches via mild electrical stimulation of the vagus nerve is now available in the United States.
The FDA has approved the use of gammaCore, the first handheld, non-invasive device to treat pain associated with episodic cluster headaches in adults.
Headaches are a common complaint in primary care, and they are often connected to sleep in a variety of ways.
Treatment of cluster headache by sphenopalatine ganglion stimulation has long-term benefits in the prevention of attacks.
Clinical Pain Advisor Articles
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Electroacupuncture May Help Reduce Opioid Use in Chronic Musculoskeletal Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis